A Bayesian phase I/II trial design for immunotherapy

DOI10.1080/01621459.2017.1383260MaRDI QIDQ4559685zbMATH OpenOpenAlexWikidataFDO

Authors Suyu Liu, Beibei Guo, Ying Yuan

Publication date 4 December 2018

Published in Journal of the American Statistical Association (Search for Journal in Brave)

Full work available at URL http://europepmc.org/articles/pmc6860919

zbMATH Keywords

immune responseimmunotherapydose findingphase I/II trialBayesian adaptive designrisk-benefit tradeoff

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian problems; characterization of Bayes procedures (62C10)

Recommendations

• A Bayesian adaptive design for addressing correlated late-onset outcomes in phase I/II randomized trials of drug combinations in oncology
• A batch‐effect adjusted Simon's two‐stage design for cancer vaccine clinical studies
• Adaptive clinical trial designs for phase I cancer studies
• scientific article; zbMATH DE number 2242805
• A Parallel Phase I/II Clinical Trial Design for Combination Therapies

Cites work

• scientific article; zbMATH DE number 2117879 (Why is no real title available?)
• Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
• Bayesian designs for phase I--II clinical trials
• Bayesian phase I/II adaptively randomized oncology trials with combined drugs
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes
• Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials

Cited in

(9)

• A Bayesian adaptive design for dual-agent phase I-II oncology trials integrating efficacy data across stages
• Biomarker-based precision dose finding for immunotherapy combined with radiotherapy
• BIPSE: a biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint
• DROID: dose-ranging approach to optimizing dose in oncology drug development
• A Bayesian design for phase I cancer therapeutic vaccine trials
• REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors
• A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications
• Hybrid design evaluating new biomarkers when there is an existing screening test
• A Bayesian adaptive phase i/II platform trial design for pediatric immunotherapy trials

This page was built for publication: A Bayesian phase I/II trial design for immunotherapy

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q4559685)